Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...

RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low ...

Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...

Some breast cancer survivors may have a slightly reduced risk for Alzheimer’s disease, though the benefit appears to be ...

Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, ...

Cite this: Cognitive Dysfunction in Postmenopausal Breast Cancer Patients on Aromatase Inhibitors - Medscape - Aug 01, 2011.

Repronovo announces first participant included in US phase 2 trial of RPN-001 to treat MALE INFERTILITY: Lausanne, Switzerland Wednesday, July 2, 2025, 14:00 Hrs [IST] ReproNovo, ...

In 2004, the American Society of Clinical Oncology reported its evaluation of the use of aromatase inhibitors (AIs) in the adjuvant treatment of postmenopausal breast cancer. While the panel endorsed ...

A new drug, camizestrant, shows promise in delaying progression of aggressive breast cancer. This treatment uses blood ...

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.